Androgen deprivation therapy associated with increased risk for fatal heart attack

the ONA take:

Androgen deprivation therapy (ADT) and radiation therapy (RT) prolong survival in men with unfavorable-risk prostate cancer; however, evidence suggests that ADT is associated with nonfatal cardiovascular events.

Specifically, long-term follow-up of a randomized clinical trial that compared ADT and RT with RT alone showed that men with significant comorbidity, most commonly prior heart attack, who received ADT died earlier. These findings are published in a research letter in the Journal of the American Medical Association.

In this study, overall survival and death due to prostate cancer, fatal heart attack, and all other causes were analyzed. The study included 206 men with unfavorable-risk prostate cancer who were randomized to receive RT alone or RT and 6 months of ADT. The men were also categorized into subgroups based on prior comorbidity, including prior heart attack.

The findings demonstrate that prior heart attack is associated with an increased risk of fatal heart in men who receive ADT for unfavorable-risk prostate cancer.

Androgen deprivation therapy associated with increased risk for fatal heart attack
Evidence suggests that androgen deprivation therapy is associated with nonfatal cardiovascular events.
Long term follow up indicates that men with comorbidity, predominately a prior heart attack, who received androgen deprivation therapy (ADT) died earlier, due to a fatal heart attack. Androgen deprivation therapy (ADT) and radiation therapy (RT) is known to prolong survival in men with unfavorable-risk prostate cancer and is considered a standard of care.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs